retrospectively analyzed NSCLC patients who received neoadjuvant chemotherapy plus PD-1 inhibitors (PD-1 + chemotherapy group) compared to those who received neoadjuvant chemotherapy alone (chemotherapy group). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.